Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0184 | 1 | 1 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0037 | 0.1412 | 1 |
Trichomonas vaginalis | hypothetical protein | 0.0184 | 1 | 1 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0184 | 1 | 1 |
Schistosoma mansoni | voltage-gated potassium channel | 0.004 | 0.1608 | 1 |
Brugia malayi | hypothetical protein | 0.003 | 0.1045 | 0.7403 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.1045 | 0.7403 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0184 | 1 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.1045 | 1 |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.0037 | 0.1412 | 1 |
Echinococcus multilocularis | Ataxin 2, N terminal,domain containing protein | 0.0014 | 0.0068 | 0.0483 |
Echinococcus granulosus | Ataxin 2 N terminaldomain containing protein | 0.0014 | 0.0068 | 0.0483 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.1045 | 0.1045 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0184 | 1 | 1 |
Entamoeba histolytica | 3-oxoacyl-(acyl-carrier protein) reductase, putative | 0.0012 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.1129 | 0.8 |
Schistosoma mansoni | hypothetical protein | 0.0014 | 0.0068 | 0.0424 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0037 | 0.1412 | 1 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0184 | 1 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.1045 | 0.1045 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Brugia malayi | hypothetical protein | 0.002 | 0.0417 | 0.2956 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.1045 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.1045 | 0.1045 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0184 | 1 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.1045 | 1 |
Schistosoma mansoni | voltage-gated potassium channel | 0.004 | 0.1608 | 1 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0184 | 1 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.1045 | 1 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0037 | 0.1412 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.1045 | 0.1045 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 5.0119 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.